Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

24.23 -0.42 (-1.70%)
Streaming Delayed Price Updated: 11:28 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 Next >
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2... 
Via Benzinga
Breaking Down Alkermes: 5 Analysts Share Their Views
Via Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Is NASDAQ:ALKS suited for growth investing?
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing? 
Via Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Via Benzinga
Exploring NASDAQ:ALKS's growth characteristics.
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Alkermes's Earnings Outlook
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
Is NASDAQ:ALKS suited for growth investing?
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
Via Chartmill
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
3 Top Pharma Stocks to Buy Now: February 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in January
These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.